An efficient early phase 2 procedure to screen medications for efficacy in smoking cessation

Psychopharmacology

Volumn 231, Issue 1, 2014, Pages 1-11

  Perkins, Kenneth A ^a   Lerman, Caryn ^b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Addiction; Medication screening; Nicotine dependence; Pharmacotherapy

Indexed keywords

AMFEBUTAMONE; MODAFINIL; NICOTINE GUM; NICOTINE PATCH; PLACEBO; VARENICLINE;

CROSSOVER PROCEDURE; DRUG COST; DRUG EFFICACY; DRUG SENSITIVITY; HUMAN; MOTIVATION; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIVITY AND SPECIFICITY; SMOKING CESSATION; VALIDATION STUDY;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BENZAZEPINES; BUPROPION; CLINICAL TRIALS, PHASE II AS TOPIC; CROSS-OVER STUDIES; DRUG EVALUATION, PRECLINICAL; FEASIBILITY STUDIES; HUMANS; QUINOXALINES; RESEARCH DESIGN; SMOKING CESSATION; VALIDATION STUDIES AS TOPIC;

EID: 84891826822     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-013-3364-6     Document Type: Review

References (92)

1. Amato L, Davoli M, Vecchi S, Ali R, Ferrell M, Faggiano F, Foxcroft D, Ling W, Minnozi S, Chengzheng Z (2011) Cochrane systematic reviews in the field of addiction: what's there and what should be. Drug Alc Dep 113:96-103
2. Ashare R, Tang KZ, Mesaros AC, Blair IA, Leone F, Strasser AA (2012) Effects of 21 days of varenicline versus placebo on smoking behaviors and urges among non-treatment seeking smokers. J Psychopharmacol 26:1383-1390
3. Ashare R, Wileyto EP, Perkins KA, Schnoll R (2013) The first seven days of a quit attempt predict relapse: validation of a measure for screening medications for nicotine dependence. J Addiction Med 7:249-254
4. Benowitz NL, Peng MW (2000) Non-nicotine pharmacotherapy for smoking cessation. CNS Drugs 13:265-285
5. Benowitz NL, Zevin S, Jacob P (1998) Suppression of nicotine intake during ad libitum cigarette smoking by high-dose transdermal nicotine. J Pharmacol Exp Ther 287:958-962
6. Bough KJ, Lerman C, Rose JE, McClernon FJ, Kenny PJ, Tyndale RF, David SP, Stein EA, Uhl GR, Conti DV, Green C, Amur S (2013) Biomarkers for smoking cessation. Clin Pharmacol Ther 93:526-536
7. Brown J, Hajek P, McRobbie H, Locker J, Gillison F, McEwen A, Beard E, West R (2013) Cigarette craving and withdrawal symptoms during temporary abstinence and the effect of nicotine gum. Psychopharmacology 229:209-218
8. Butz RF, Morelli G (2008) Innovative strategies for early clinical R&D. iDrugs 11:36-41
9. Carpenter MJ, Hughes JR, Gray KM, Wahlquist AE, Saladin ME, Alberg AJ (2011) Nicotine therapy sampling to induce quit attempts among smokers unmotivated to quit. Arch Intern Med 171:1901-1907
10. Centers for Disease Control and Prevention (CDCP) (2011) Quitting smoking among adults - United States, 2001-2010. Morb Mortal Wkly Rep 60:1513-1519
11. Cleophas TJM (1993) Cross-over studies: a modified analysis with more power. Clin Pharmacol Ther 53:515-520
12. Cohen J (1988) Statistical power analysis for the social sciences, 2nd edn. Lawrence Erlbaum Associates, Hillsdale
13. Cousins MS, Stamat HM, de Wit H (2001) Acute doses of d-amphetamine and bupropion increase cigarette smoking. Psychopharmacology (Berl) 157:243-253
14. Cummings KM, Hyland A (2005) Impact of nicotine replacement therapy on smoking behavior. Ann Rev Public Health 26:583-599
15. DiMasi JA, Hansen RW, Grabowski HG (2003) The price of innovation: new estimates of drug development costs. J Health Economics 22:151-185
16. Farid P, Abate MA (1998) Buspirone use for smoking cessation. Annals Pharmacother 32:1362-1364
17. Ferguson SG, Gitchell JG, Shiffman S, Sembower MA (2009) Prediction of abstinence at 10 weeks based on smoking status at 2 weeks during a quit attempt. Clin Ther 31:1957-1965
18. Ferry L (1999) Non-nicotine pharmacotherapy for smoking cessation. Prim Care 26:653-669
19. Ferry LH, Burchette RJ (1994) Efficacy of bupropion for smoking cessation in non-depressed smokers. J Addict Dis 13:249
20. Fleiss JL (1986) The design and analysis of clinical experiments. Wiley, New York
21. Fleiss JL (1989) A critique of recent research on the two-treatment crossover design. Controlled Clin Trials 10:237-243
22. Fletcher DJ, Lewis SM, Matthews JNS (1990) Factorial designs for crossover clinical trials. Stat Med 9:1121-1129
23. Foulds J, Steinberg MB, Williams JM, Ziedonis D (2006) Developments in pharmacotherapy for tobacco dependence: past, present and future. Drug Alc Rev 25:59-71
24. Foulds J, Russ C, Yu C-R, Zou KH, Galaznik A, Franzon M, Berg A, Hughes JR (2013) Effects of varenicline on individual nicotine withdrawal symptoms: a combined analysis of eight randomized, placebo-controlled trials. Nic Tobacco Res 15:1849-1857
25. Giovino GA, Mirza SA, Samet JM, Gupta PC, Jarvis MJ, Bahla N, Doll R et al (2012) Tobacco use in 3 billion individuals from 16 countries: an analysis of nationally representative cross-sectional household surveys. Lancet 380:668-679
26. Glaros AG, Kline RB (1988) Understanding the accuracy of tests with cutting scores: the sensitivity, specificity, and predictive value model. J Clinical Psychol 44:1013-1023
27. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, Watsky EJ, Gong J, Williams KE, Reeves KR (2006) Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs. sustained-release bupropion and placebo for smoking cessation. JAMA 296:47-55
28. Gorodetzky CW, Grudzinkas C (2005) Involving the pharmaceutical and biotech communities in medication development for substance abuse. Pharmacol Ther 108:109-118
29. Harmey D, Griffin PR, Kenny PJ (2012) Development of novel pharmacotherapeutics for tobacco dependence: progress and future directions. Nic Tobacco Res 14:1300-1318
30. Hughes JR (2011) The hardening hypothesis: is the ability to quit decreasing due to increasing nicotine dependence? A review and commentary. Drug Alc Dep 117:111-117
31. Hughes JR, Stead L, Lancaster T (2004) Antidepressants for smoking cessation. Cochrane Database Syst Rev 4, CD000031
32. Hughes JR, Marcy TW, Naud S (2009) Interest in treatments to stop smoking. J Substance Abuse Treatment 36:18-24
33. Issa JS, Abe TO, Moura S, Santos PCJL, Pereira AC (2013) Effectiveness of coadministration of varenicline, bupropion, and serotonin reuptake inhibitors in a smoking cessation program in the real-life setting. Nic Tobacco Res 15:1146-1150
34. Javors MA, Hatch JP, Lamb RJ (2005) Cut-off levels for breath carbon monoxide as a marker for cigarette smoking. Addiction 100:159-167
35. Jupp B, Lawrence AJ (2009) New horizons for therapeutics in drug and alcohol abuse. Pharmacol Ther 125:138-168
36. Kenford SL, Fiore MC, Jorenby DE, Smith SS, Wetter D, Baker TB (1994) Predicting smoking cessation. Who will quit with and without the nicotine patch. JAMA 271:589-594
37. Koch GG, Amara IA, Brown BW, Colton T, Gillings DB (1989) A two-period crossover design for the comparison of two active treatments and placebo. Stat Med 8:487-504
38. Kola I (2008) The state of innovation in drug development. Clin Pharm Ther 83:227-230
39. Kollins SH, McClernon FJ, Van Voorhees EV (2010) Monetary incentives promote smoking abstinence in adults with Attention Deficit Hyperactivity Disorder (ADHD). Exper Clin Psychopharmacol 18:221-228
40. Koob GF, Lloyd GK, Mason BJ (2009) Development of pharmacotherapies for drug addiction: a Rosetta Stone approach. Nature Rev Drug Disc 8:500-515
41. Kroboth PD, Schmith VD, Smith RB (1991) Pharmacodynamic modeling: application to new drug development. Clin Pharmacokin 20:91-98
42. Lamb RJ, Kirby KC, Morral AR, Balbicka G, Iguchi MY (2010) Shaping smoking cessation in hard-to-treat smokers. J Consult Clin Psychol 78:62-71
43. Lerman C, Roth D, Kaufmann V, Audrain J, Hawk L, Liu A, Niaura R, Epstein L (2002) Mediating mechanisms for the impact of bupropion in smoking cessation treatment. Drug Alc Depend 67:219-223
44. Lerman C, LeSage MG, Perkins KA, O'Malley SS, Siegel SJ, Benowitz NL, Corrigall WA (2007) Translational research in medication development for nicotine dependence. Nature Rev Drug Dev 6:746-762
45. Lesko LJ (2007) Paving the critical path: how can clinical pharmacology help achieve the vision? Clin Pharm Ther 81:170-177
46. Levy DE, Thorndike AN, Biener L, Rigotti NA (2007) Use of nicotine replacement therapy to reduce or delay smoking but not to quit: prevalence and association with subsequent cessation efforts. Tob Control 16:384-389
47. Loh W-Y, Piper ME, Schlam TR, Fiore MC, Smith SS, Jorenby DE, Cook JW, Bolt DM, Baker TB (2012) Should all smokers use combination smoking cessation pharmacotherapy? Nic Tobacco Res 14:131-141
48. Mahtani KR, Heneghan CJ, Glasziou PP, Perera R (2011) Reminder packaging for improving adherence to self-administered long-term medications. Cochrane Database Syst Rev 9, CD005025
49. McCormick J, Olsen J (2013) The European Union: politics and policies, 5th edn. Westview Press, Boulder
50. McKee SA, Weinberger AH, Shi J, Tetrault J, Coppola S (2012) Developing and validating a human laboratory model to screen medications for smoking cessation. Nic Tobacco Res 14:1362-1371
51. Miczek KA, de Wit H (2008) Challenges for translational psychopharmacology research - some basic principles. Psychopharmacology 199:291-301
52. Mills EJ, Wu P, Lockhart I, Thorlund K, Puhan M, Ebbert JO (2012) Comparisons of high-dose and combination nicotine replacement therapy, varenicline, and bupropion for smoking cessation: a systematic review and multiple treatment meta-analysis. Annals Med 44:588-597
53. Mueller ET, Landes RD, Kowal BP, Yi R, Stitzer ML, Burnett CA, Bickel WK (2009) Delay of smoking gratification as a laboratory model of relapse: effects of incentives for not smoking, and relationship with measures of executive function. Behav Pharmacol 20:461-473
54. Mulligan SC, Masterson JG, Devane JG, Kelly JG (1990) Clinical and pharmacokinetic properties of a transdermal nicotine patch. Clin Pharmacol Ther 47:331-337
55. Parodi O, Simonetti I, Michelassi C, Carpeggiani C, Biagini A, LAbbate A, Maseri A (1986) Comparison of verapamil and propranolol therapy for angina pectoris at rest: a randomized, multiple-crossover, controlled trial in the coronary care unit. Amer J Cardiology 57:899-906
56. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht AL (2010) How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nature Rev Drug Discov 9:203-214
57. Perkins KA, Lerman C (2011) Early human screening of medications to treat drug addiction: novel paradigms and the relevance of pharmacogenetics. Clin Pharmacol Ther 89:460-463
58. Perkins KA, Marcus MD, Levine MD, D'Amico D, Miller A, Broge M, Ashcom J, Shiffman S (2001) Cognitive-behavioral therapy to reduce weight concerns improves smoking cessation outcome in weight-concerned women. J Consult Clin Psychol 69:604-613
59. Perkins KA, Stitzer M, Lerman C (2006) Medication screening for smoking cessation: a proposal for new methodologies. Psychopharmacology 184:628-636
60. Perkins KA, Conklin CA, Levine MD (2008a) Cognitive-behavioral therapy for smoking cessation: a practical guide to the most effective treatments. Routledge, New York
61. Perkins KA, Lerman C, Stitzer ML, Fonte CA, Briski JL, Scott JA, Chengappa KNR (2008b) Development of procedures for early human screening of smoking cessation medications. Clin Pharmacol Ther 84:216-221
62. Perkins KA, Briski J, Fonte C, Scott J, Lerman C (2009) Severity of tobacco abstinence symptoms varies by time of day. Nic Tobacco Res 11:84-91
63. Perkins KA, Lerman C, Fonte C, Mercincavage M, Stitzer ML, Chengappa KRN, Jain A (2010) Cross-validation of a new procedure for early screening of smoking cessation medications in humans. Clin Pharmacol Ther 88:109-114
64. Perkins KA, Karelitz JL, Jao NC (2013a) Optimal carbon monoxide criteria to confirm 24-h smoking abstinence. Nic Tobacco Res 15:578-582
65. Perkins KA, Lerman C, Karelitz JL, Jao NC, Chengappa KNR, Sparks GM (2013b) Sensitivity and specificity of a procedure for early human screening of novel smoking cessation medications. Addiction 108:1962-1968
66. Pierce RC, O'Brien CP, Kenny PJ, Vanderschuren LJMJ (2012) Rational development of addiction pharmacotherapies: successes, failures, and prospects. Cold Spring Harb Perspect Med 2:1-8, article number a012880
67. Polosa R, Benowitz NL (2011) Treatment of nicotine addiction: present therapeutic options and pipeline developments. Trends Pharmacol Sci 32:281-289
68. Ray LA, Hutchison KE, Tartter M (2010) Application of human laboratory models to pharmacotherapy development for alcohol dependence. Curr Pharmaceutical Design 16:2149-2158
69. Romanowich P, Lamb RJ (2010a) Effects of escalating and descending schedules of incentives on cigarette smoking in smokers without plans to quit. J Applied Behav Analysis 43:357-367
70. Romanowich P, Lamb RJ (2010b) The relationship between in-treatment abstinence and post-treatment abstinence in a smoking cessation treatment. Exper Clin Psychopharmacol 18:32-36
71. Rostron B (2013) Smoking-attributable mortality by cause in the United States: revising the CDC's data and estimates. Nic Tobacco Res 15:238-246
72. Schnoll RA, Lerman C (2006) Current and emerging pharmacotherapies for treating tobacco dependence. Expert Opin Emerg Drugs 11:429-444
73. Schnoll RA, Wileyto EP, Pinto A, Leone F, Gariti P, Siegel S, Perkins KA, Dackis C, Heitjan BW, Lerman C (2008) A placebo-controlled trial of modafinil for nicotine dependence. Drug Alc Depend 98:86-93
74. Sheiner LB (1997) Learning versus confirming in clinical drug development. Clin Pharmacol Ther 61:275-291
75. Shiffman S (2007) Use of more nicotine lozenges leads to better success in quitting smoking. Addiction 102:809-814
76. Shiffman S, Johnston JA, Khayrallah M, Elash CA, Gwaltney CJ, Paty JA, Evoniuk G, DeVeaugh-Geiss J (2000) The effect of bupropion on nicotine craving and withdrawal. Psychopharmacology 148:33-40
77. Shiffman S, Ferguson SG, Gwaltney CJ, Balabanis MH, Shadel WG (2006) Reduction of abstinence-induced withdrawal and craving using high-dose nicotine replacement therapy. Psychopharmacology 184:637-644
78. Shiltz D, Paniagua A, Hastings JE (2011) A retrospective comparison of varenicline monotherapy versus the combination of varenicline and bupropion or bupropion and nicotine patches in a VA tobacco cessation clinic. J Smoking Cessation 6:65-73
79. Sofuoglu M, Waters AJ, Mooney M (2008) Modafinil and nicotine interactions in abstinent smokers. Hum Psychopharmacol 23:21-30
80. Song F, Harvey I, Lilford R (2008) Adjusted indirect comparison may be less biased than direct comparison for evaluating new pharmaceutical interventions. J Clin Epid 61:455-463
81. SRNT Subcommittee on Biochemical Verification (2002) Biochemical verification of tobacco use and cessation. Nic Tobacco Res 4:149-159
82. Stead LF, Lancaster T (2007) Interventions to reduce harm from continued tobacco use. Cochrane Database Syst Rev 3, CD005231
83. Stitzer ML, Rand CS, Below GE, Mead AM (1986) Contingent payment procedures for smoking reduction and cessation. J Appl Beh Analysis 19:197-202
84. Streiner DL (2007) Alternatives to placebo-controlled trials. Can J Neurol Sci 34(suppl 1):S37-S41
85. Teneggi V, Tiffany ST, Squassante L, Milleri S, Ziviani L, Bye A (2002) Smokers deprived of cigarettes for 72 h: effect of nicotine patches on craving and withdrawal. Psychopharmacology 164:177-187
86. US Dept of Health and Human Services (USDHHS, 2004) Innovation or stagnation: challenge and opportunity on the critical path to new medical products. (FDA Critical Path Initiative whitepaper.) Bethesda MD: USDHHS
87. US Dept of Health and Human Services (USDHHS, 2010) How tobacco smoke causes disease: the biological and behavioral basis for smoking-attributable disease. (A report of the Surgeon General.) Atlanta: USDHHS
88. US Dept of Health, Education and Welfare (USDHEW, 1964) Smoking and health: report of the Advisory Committee to the Surgeon General of the Public Health Service. Washington: USDHEW, PHS, Center for Disease Control, 1964. PHS Publication No. 1103
89. Vocci FJ (1996) Development of medications for addictive disorders. In: Schuster CR, Kuhar M (eds) Handbook of experimental pharmacology, vol. 118: pharmacological aspects of drug dependence, towards an integrated neurobehavioral approach. Springer Verlag, Berlin, pp 473-485
90. Wewers ME, Stillman FA, Harman AM, Shopland DR (2003) Distribution of daily smokers by stage of change: current population survey results. Preventive Med 36:710-720
91. Wileyto EP, Patterson F, Niaura R, Epstein LH, Brown RA, Audrain-McGovern J, Hawk LW, Lerman C (2004) Do small lapses predict relapse to smoking behavior under bupropion treatment? Nic Tobacco Res 6:357-367
92. Woodcock J, Woosley R (2008) The FDA Critical Path Initiative and its influence on new drug development. Ann Rev Med 59:1-12